BeiGene Ltd
$
120.32
-1.06 (-0.87%)
| Volume: | 215,662 | Avg Vol (1m): | 304,739 |
| Market Cap $: | 7.24 Bil | Enterprise Value $: | 5.88 Bil |
| P/E (TTM): | 0.00 | P/B: | 4.47 |
| Earnings Power Value | -128.85 |
| Net Current Asset Value | 20.64 |
| Tangible Book | 26.82 |
| Projected FCF | 0 |
| Median P/S Value | 152.71 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 6/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 6.68 |
Cash-To-Debt ranked
lower than
59.65%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
BGNE:
6.68
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.14, Med: 7.55, Max: 39.79
Current: 6.68
|
| Equity-to-Asset | 0.74 |
Equity-to-Asset ranked
higher than
55.96%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
BGNE:
0.74
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: -0.48, Med: 0.74, Max: 0.92
Current: 0.74
|
| Debt-to-Equity | 0.15 |
Debt-to-Equity ranked
higher than
62.80%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
BGNE:
0.15
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: -0.71, Med: 0.12, Max: 0.6
Current: 0.15
|
| Debt-to-EBITDA | -0.32 |
Debt-to-EBITDA ranked
lower than
100.00%
of
196
companies
in the
Biotechnology
industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
BGNE:
-0.32
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: -8.7, Med: -0.68, Max: -0.15
Current: -0.32
|
| Piotroski F-Score | 2 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 7.02 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -0.76 |
Not Manipulator
Manipulator
| |
Profitability & Growth : 4/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -315.55 |
Operating Margin ranked
higher than
53.79%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
BGNE:
-315.55
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -10940.19, Med: -238.47, Max: -41.3
Current: -315.55
|
| Net Margin % | -302.45 |
Net Margin ranked
higher than
54.67%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
BGNE:
-302.45
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -11141.78, Med: -240.07, Max: -39.06
Current: -302.45
|
| ROE % | -46.76 |
ROE ranked
higher than
58.34%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
BGNE:
-46.76
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -114.09, Med: -55.89, Max: -18.25
Current: -46.76
|
| ROA % | -36.13 |
ROA ranked
higher than
62.08%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
BGNE:
-36.13
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -67.02, Med: -50.76, Max: -12.85
Current: -36.13
|
| ROC (Joel Greenblatt) % | -537.20 |
ROC (Joel Greenblatt) ranked
higher than
53.38%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
BGNE:
-537.2
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -904.62, Med: -376.08, Max: -67.2
Current: -537.2
|
| 3-Year Total Revenue Growth Rate | 183.10 |
3-Year Revenue Growth Rate ranked
higher than
95.24%
of
651
companies
in the
Biotechnology
industry.
Industry Max: 906.3, Med: 1.1, Min: -100
BGNE:
134.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: -45, Med: 134.4, Max: 185.1
Current: 134.4
|
| 3-Year Total EBITDA Growth Rate | -133.40 |
3-Year EBITDA Growth Rate ranked
lower than
88.53%
of
802
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
BGNE:
-93.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: -294.7, Med: -103.1, Max: -93.3
Current: -93.3
|
» BGNE's 30-Y Financials
Financials (Next Earnings Date: 2019-08-09)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:BGNE
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2834 |
| Compare | NAS:SAGE NAS:NBIX NAS:EXEL NAS:SGEN XKRX:215600 NAS:IONS TSE:4587 NAS:TECH HKSE:01530 HKSE:01548 NAS:ALKS BOM:532523 XKRX:128940 NAS:SRPT NAS:JAZZ NAS:BLUE SZSE:000661 NAS:AGIO OSTO:SOBI NAS:UTHR |
| Traded in other countries | 49BA.Germany 06160.Hongkong |
| Address | c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108 |
| BeiGene Ltd is a United States based clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 4.47 |
PB Ratio ranked
lower than
71.10%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
BGNE:
4.47
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 3.19, Med: 4.6, Max: 5.35
Current: 4.47
|
| PS Ratio | 28.53 |
PS Ratio ranked
lower than
64.05%
of
726
companies
in the
Biotechnology
industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
BGNE:
28.53
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 28.24, Med: 36.24, Max: 58.56
Current: 28.53
|
| EV-to-EBIT | -7.64 |
EV-to-EBIT ranked
lower than
100.00%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
BGNE:
-7.64
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -15.2, Med: -8.95, Max: -7.5
Current: -7.64
|
| EV-to-EBITDA | -7.75 |
EV-to-EBITDA ranked
lower than
100.00%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
BGNE:
-7.75
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -15.5, Med: -9.15, Max: -7.6
Current: -7.75
|
| EV-to-Revenue | 24.08 |
EV-to-Revenue ranked
higher than
99.61%
of
771
companies
in the
Biotechnology
industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
BGNE:
24.08
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 23.6, Med: 30.75, Max: 51.1
Current: 24.08
|
| Current Ratio | 7.52 |
Current Ratio ranked
higher than
70.48%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
BGNE:
7.52
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 0.14, Med: 7.71, Max: 15.91
Current: 7.52
|
| Quick Ratio | 7.47 |
Quick Ratio ranked
higher than
70.95%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
BGNE:
7.47
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.14, Med: 7.65, Max: 15.91
Current: 7.47
|
| Days Inventory | 5.83 |
Days Inventory ranked
lower than
55.72%
of
481
companies
in the
Biotechnology
industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
BGNE:
5.83
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 5.83, Med: 7.14, Max: 7.28
Current: 5.83
|
| Days Sales Outstanding | 88.52 |
Days Sales Outstanding ranked
higher than
73.65%
of
668
companies
in the
Biotechnology
industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
BGNE:
88.52
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 45.06, Med: 60.33, Max: 88.52
Current: 88.52
|
| Days Payable | 48.92 |
Days Payable ranked
lower than
98.88%
of
536
companies
in the
Biotechnology
industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
BGNE:
48.92
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 44.52, Med: 56.1, Max: 92.96
Current: 48.92
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -20.70 |
3-Year Share Buyback Rate ranked
lower than
67.91%
of
857
companies
in the
Biotechnology
industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
BGNE:
-20.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -20.7, Med: 4.7, Max: 9
Current: -20.7
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.49 |
Price-to-Tangible-Book ranked
lower than
64.09%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
BGNE:
4.49
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 4.46, Med: 4.8, Max: 5.24
Current: 4.49
|
| Price-to-Median-PS-Value | 0.79 |
Price-to-Median-PS-Value ranked
higher than
90.41%
of
678
companies
in the
Biotechnology
industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
BGNE:
0.79
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.78, Med: 1.08, Max: 1.61
Current: 0.79
|
| Earnings Yield (Joel Greenblatt) % | -13.13 |
Earnings Yield (Greenblatt) ranked
lower than
97.78%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
BGNE:
-13.13
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -13.3, Med: -11.15, Max: -6.6
Current: -13.13
|
More Statistics
| Revenue (TTM) (Mil) $ | 243.51 |
| EPS (TTM) $ | -12.74 |
| Beta | 1.3 |
| Volatility % | 51.58 |
| 52-Week Range $ | 105.19 - 194.56 |
| Shares Outstanding (Mil) | 59.81 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 2 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | N |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |